Role of Suzetrigine as a Part of a Multimodal Regimen to Red... | Clinical Trial | StuddyBuddy@endsection Role of Suzetrigine as a Part of a Multimodal Regimen to Reduce Pain and Opioid Use After Total Knee Arthroplasty
Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Not Yet Recruiting NCT07624526

Role of Suzetrigine as a Part of a Multimodal Regimen to Reduce Pain and Opioid Use After Total Knee Arthroplasty

Conditions: Knee Arthritis, Knee Osteoarthritis

Sex: All
Ages: 18 Years – 95 Years
Healthy volunteers: No
Phase: PHASE4
Enrollment: 75
Sponsor: Emory University

Location: Emory Clinic Atlanta Georgia

Summary

This study is a prospective, single-arm interventional trial enrolling patients undergoing total knee arthroplasty (TKA) for knee arthritis. All participants will receive Suzetrigine (brand name Journavx by Vertex Pharma) as part of a standardized multimodal perioperative analgesic regimen in addition to standard of care.

Eligibility Criteria

Inclusion Criteria: * Patients undergoing primary total knee arthroplasty for osteoarthritis of the knee. * Patients between the ages of 18 and 95 years. Exclusion Criteria: * Patients with concurrent and significant injuries to other bones or organs. * Patients with local infections. * Minors unable to provide informed consent for participation in the study. * Subjects who, in the opinion of the investigator, may be non-compliant with study schedules or procedures. * Patients with pre-existing immune suppression, where further immune suppression with GCs could warrant unwarranted or unneeded risk. * Patients with preoperative opioid use, defined as daily use less than 4 weeks before the index surgery. * Patients with a history of severe heart disease (NYHA2), renal failure, or liver dysfunction * Patients with active peptic ulcer disease. * Patients neurological or psychiatric diseases, potentially influencing pain perception * Patients who are pregnant. * Patients with a history of alcohol or medical abuse, allergies to glucocorticoids, current daily use of glucocorticoids. * Patients who are unable to take NSAIDs. * Patients who receive Deep Venous Thrombosis (DVT) prophylaxis different than Aspirin (81mg) twice daily (BID). * Patients who have known diabetes mellitus as defined with an A1C greater than 6.5%. * Patients currently taking CYP3A inhibitors

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07624526). StuddyBuddy aggregates publicly available trial information.